New Jersey Assembly Bill A3251

New Jersey 2022-2023 Regular Session

• Introduced: 3/7/22
• Refer: 3/7/22

Caption

Requires health insurers, SHBP, and SEHBP to provide coverage for medication and treatment for hepatitis C.

Impact

The enactment of A3251 will potentially result in significant changes to how health insurance plans operate concerning hepatitis C treatments. By mandating coverage, it aims to make essential treatments more accessible to individuals who might otherwise be unable to afford them due to insurance limitations. This could lead to increased treatment rates and better health outcomes for those affected by the virus, ultimately reducing the disease's prevalence in the state.

Summary

Assembly Bill A3251 aims to ensure that health benefits plans in New Jersey, including those from health insurers and government employee plans, provide coverage for medications and treatments related to hepatitis C. The bill stipulates that coverage cannot be denied based on a patient's history of drug or alcohol use, the stage of the disease, or the specialization of the prescribing healthcare professional. This initiative seeks to enhance access to treatment for hepatitis C, addressing both public health and insurance equity.

Contention

Despite the positive intentions, discussions around the bill may focus on concerns regarding its financial implications for health insurance providers. Detractors might argue that the mandatory coverage could lead to increased premiums for policyholders or strain the financial models of smaller insurance companies. Conversely, advocates may emphasize the moral obligation to provide comprehensive healthcare coverage to all individuals suffering from hepatitis C, regardless of their circumstances.